Menochet K[au] - Search Results

Year	Number of Results
2010	1
2011	2
2012	2
2018	2
2019	2
2020	1
2021	2
2022	2
2023	3
2024	0

1

PK/PD and Bioanalytical Considerations of AAV-Based Gene Therapies: an IQ Consortium Industry Position Paper.

Kavita U, Sun K, Braun M, Lembke W, Mody H, Kamerud J, Yang TY, Braun IV, Fang X, Gao W, Gupta S, Hofer M, Liao MZ, Loo L, McBlane F, Menochet K, Stubenrauch KG, Upreti VV, Vigil A, Wiethoff CM, Xia CQ, Zhu X, Jawa V, Chemuturi N. Kavita U, et al. Among authors: menochet k. AAPS J. 2023 Jul 31;25(5):78. doi: 10.1208/s12248-023-00842-1. AAPS J. 2023. PMID: 37523051 Review.

2

Serum albumin binding knob domains engineered within a V_H framework III bispecific antibody format and as chimeric peptides.

Adams R, Joyce C, Kuravskiy M, Harrison K, Ahdash Z, Balmforth M, Chia K, Marceddu C, Coates M, Snowden J, Goursaud E, Ménochet K, van den Elsen J, Payne RJ, Lawson ADG, Scott-Tucker A, Macpherson A. Adams R, et al. Among authors: menochet k. Front Immunol. 2023 May 12;14:1170357. doi: 10.3389/fimmu.2023.1170357. eCollection 2023. Front Immunol. 2023. PMID: 37251411 Free PMC article.

3

Designing Out PXR Activity on Drug Discovery Projects: A Review of Structure-Based Methods, Empirical and Computational Approaches.

Hall A, Chanteux H, Ménochet K, Ledecq M, Schulze MED. Hall A, et al. Among authors: menochet k. J Med Chem. 2021 May 27;64(10):6413-6522. doi: 10.1021/acs.jmedchem.0c02245. Epub 2021 May 18. J Med Chem. 2021. PMID: 34003642 Review.

4

Non-human primates in the PKPD evaluation of biologics: Needs and options to reduce, refine, and replace. A BioSafe White Paper.

Ménochet K, Yu H, Wang B, Tibbitts J, Hsu CP, Kamath AV, Richter WF, Baumann A. Ménochet K, et al. MAbs. 2022 Jan-Dec;14(1):2145997. doi: 10.1080/19420862.2022.2145997. MAbs. 2022. PMID: 36418217 Free PMC article. Review.

5

TRYBE®: an Fc-free antibody format with three monovalent targeting arms engineered for long in vivo half-life.

Davé E, Durrant O, Dhami N, Compson J, Broadbridge J, Archer S, Maroof A, Whale K, Menochet K, Bonnaillie P, Barry E, Wild G, Peerboom C, Bhatta P, Ellis M, Hinchliffe M, Humphreys DP, Heywood SP. Davé E, et al. Among authors: menochet k. MAbs. 2023 Jan-Dec;15(1):2160229. doi: 10.1080/19420862.2022.2160229. MAbs. 2023. PMID: 36788124 Free PMC article.

6

Use of selective substrates and inhibitors to rapidly characterise batches of cryopreserved primary human hepatocytes for assessment of active uptake liability in drug discovery and development.

Golding M, Light O, Williamson B, Ménochet K. Golding M, et al. Among authors: menochet k. Xenobiotica. 2022 Aug;52(8):868-877. doi: 10.1080/00498254.2022.2124388. Xenobiotica. 2022. PMID: 36121307

7

PBPK Model of Coproporphyrin I: Evaluation of the Impact of SLCO1B1 Genotype, Ethnicity, and Sex on its Inter-Individual Variability.

Takita H, Barnett S, Zhang Y, Ménochet K, Shen H, Ogungbenro K, Galetin A. Takita H, et al. Among authors: menochet k. CPT Pharmacometrics Syst Pharmacol. 2021 Feb;10(2):137-147. doi: 10.1002/psp4.12582. Epub 2021 Jan 19. CPT Pharmacometrics Syst Pharmacol. 2021. PMID: 33289952 Free PMC article.

8

A mechanistic modelling approach for the determination of the mechanisms of inhibition by cyclosporine on the uptake and metabolism of atorvastatin in rat hepatocytes using a high throughput uptake method.

Carter SJ, Ferecskó AS, King L, Ménochet K, Parton T, Chappell MJ. Carter SJ, et al. Among authors: menochet k. Xenobiotica. 2020 Apr;50(4):415-426. doi: 10.1080/00498254.2019.1652781. Epub 2019 Aug 19. Xenobiotica. 2020. PMID: 31389297

9

Gaining Mechanistic Insight Into Coproporphyrin I as Endogenous Biomarker for OATP1B-Mediated Drug-Drug Interactions Using Population Pharmacokinetic Modeling and Simulation.

Barnett S, Ogungbenro K, Ménochet K, Shen H, Lai Y, Humphreys WG, Galetin A. Barnett S, et al. Among authors: menochet k. Clin Pharmacol Ther. 2018 Sep;104(3):564-574. doi: 10.1002/cpt.983. Epub 2018 Jan 17. Clin Pharmacol Ther. 2018. PMID: 29243231 Free PMC article.

10

Comprehensive Evaluation of the Utility of 20 Endogenous Molecules as Biomarkers of OATP1B Inhibition Compared with Rosuvastatin and Coproporphyrin I.

Barnett S, Ogungbenro K, Ménochet K, Shen H, Humphreys WG, Galetin A. Barnett S, et al. Among authors: menochet k. J Pharmacol Exp Ther. 2019 Jan;368(1):125-135. doi: 10.1124/jpet.118.253062. Epub 2018 Oct 12. J Pharmacol Exp Ther. 2019. PMID: 30314992

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

14 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Results by year